466 related articles for article (PubMed ID: 16418786)
1. Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: a 3-year randomized placebo-controlled trial.
Chevrel G; Schott AM; Fontanges E; Charrin JE; Lina-Granade G; Duboeuf F; Garnero P; Arlot M; Raynal C; Meunier PJ
J Bone Miner Res; 2006 Feb; 21(2):300-6. PubMed ID: 16418786
[TBL] [Abstract][Full Text] [Related]
2. A phase 3, double-blind, randomised, parallel-group, placebo-controlled study of oral weekly alendronate for the prevention of androgen deprivation bone loss in nonmetastatic prostate cancer: the Cancer and Osteoporosis Research with Alendronate and Leuprolide (CORAL) study.
Klotz LH; McNeill IY; Kebabdjian M; Zhang L; Chin JL;
Eur Urol; 2013 May; 63(5):927-35. PubMed ID: 23040208
[TBL] [Abstract][Full Text] [Related]
3. Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low-dose prednisone: a randomized, double-blind, placebo-controlled trial.
Lems WF; Lodder MC; Lips P; Bijlsma JW; Geusens P; Schrameijer N; van de Ven CM; Dijkmans BA
Osteoporos Int; 2006; 17(5):716-23. PubMed ID: 16463007
[TBL] [Abstract][Full Text] [Related]
4. Two-year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta.
DiMeglio LA; Peacock M
J Bone Miner Res; 2006 Jan; 21(1):132-40. PubMed ID: 16355282
[TBL] [Abstract][Full Text] [Related]
5. Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo-controlled study.
Ward LM; Rauch F; Whyte MP; D'Astous J; Gates PE; Grogan D; Lester EL; McCall RE; Pressly TA; Sanders JO; Smith PA; Steiner RD; Sullivan E; Tyerman G; Smith-Wright DL; Verbruggen N; Heyden N; Lombardi A; Glorieux FH
J Clin Endocrinol Metab; 2011 Feb; 96(2):355-64. PubMed ID: 21106710
[TBL] [Abstract][Full Text] [Related]
6. Risedronate in children with osteogenesis imperfecta: a randomised, double-blind, placebo-controlled trial.
Bishop N; Adami S; Ahmed SF; Antón J; Arundel P; Burren CP; Devogelaer JP; Hangartner T; Hosszú E; Lane JM; Lorenc R; Mäkitie O; Munns CF; Paredes A; Pavlov H; Plotkin H; Raggio CL; Reyes ML; Schoenau E; Semler O; Sillence DO; Steiner RD
Lancet; 2013 Oct; 382(9902):1424-32. PubMed ID: 23927913
[TBL] [Abstract][Full Text] [Related]
7. Risedronate in the treatment of mild pediatric osteogenesis imperfecta: a randomized placebo-controlled study.
Rauch F; Munns CF; Land C; Cheung M; Glorieux FH
J Bone Miner Res; 2009 Jul; 24(7):1282-9. PubMed ID: 19257821
[TBL] [Abstract][Full Text] [Related]
8. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension.
Ensrud KE; Barrett-Connor EL; Schwartz A; Santora AC; Bauer DC; Suryawanshi S; Feldstein A; Haskell WL; Hochberg MC; Torner JC; Lombardi A; Black DM;
J Bone Miner Res; 2004 Aug; 19(8):1259-69. PubMed ID: 15231012
[TBL] [Abstract][Full Text] [Related]
9. THE CLINICAL CHARACTERISTICS AND EFFICACY OF BISPHOSPHONATES IN AUDLT PATIENTS WITH OSTEOGENESIS IMPERGECTA.
Xu XJ; Ma DD; Lv F; Wang JY; Liu Y; Xia WB; Jiang Y; Wang O; Xing XP; Yu W; Li M
Endocr Pract; 2016 Nov; 22(11):1267-1276. PubMed ID: 27482615
[TBL] [Abstract][Full Text] [Related]
10. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial.
Greenspan SL; Parker RA; Ferguson L; Rosen HN; Maitland-Ramsey L; Karpf DB
J Bone Miner Res; 1998 Sep; 13(9):1431-8. PubMed ID: 9738515
[TBL] [Abstract][Full Text] [Related]
11. Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial.
Khan AA; Bilezikian JP; Kung AW; Ahmed MM; Dubois SJ; Ho AY; Schussheim D; Rubin MR; Shaikh AM; Silverberg SJ; Standish TI; Syed Z; Syed ZA
J Clin Endocrinol Metab; 2004 Jul; 89(7):3319-25. PubMed ID: 15240609
[TBL] [Abstract][Full Text] [Related]
12. Additional beneficial effects of alendronate in growth hormone (GH)-deficient adults with osteoporosis receiving long-term recombinant human GH replacement therapy: a randomized controlled trial.
Biermasz NR; Hamdy NA; Janssen YJ; Roelfsema F
J Clin Endocrinol Metab; 2001 Jul; 86(7):3079-85. PubMed ID: 11443170
[TBL] [Abstract][Full Text] [Related]
13. Once-weekly oral alendronate 70 mg in patients with glucocorticoid-induced bone loss: a 12-month randomized, placebo-controlled clinical trial.
Stoch SA; Saag KG; Greenwald M; Sebba AI; Cohen S; Verbruggen N; Giezek H; West J; Schnitzer TJ
J Rheumatol; 2009 Aug; 36(8):1705-14. PubMed ID: 19487264
[TBL] [Abstract][Full Text] [Related]
14. Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis.
Li M; Zhang ZL; Liao EY; Chen DC; Liu J; Tao TZ; Wu W; Xia WB; Lu YJ; Sheng ZF; Lu CY; Meng GL; Xu L; Zhang WJ; Hu YY; Xu L
Menopause; 2013 Jan; 20(1):72-8. PubMed ID: 22968256
[TBL] [Abstract][Full Text] [Related]
15. EFFECTS OF LONG-TERM ALENDRONATE TREATMENT ON A LARGE SAMPLE OF PEDIATRIC PATIENTS WITH OSTEOGENESIS IMPERFECTA.
Lv F; Liu Y; Xu X; Wang J; Ma D; Jiang Y; Wang O; Xia W; Xing X; Yu W; Li M
Endocr Pract; 2016 Dec; 22(12):1369-1376. PubMed ID: 27482608
[TBL] [Abstract][Full Text] [Related]
16. Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis.
McClung MR; Wasnich RD; Recker R; Cauley JA; Chesnut CH; Ensrud KE; Burdeska A; Mills T;
J Bone Miner Res; 2004 Jan; 19(1):11-8. PubMed ID: 14753731
[TBL] [Abstract][Full Text] [Related]
17. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial.
Black DM; Schwartz AV; Ensrud KE; Cauley JA; Levis S; Quandt SA; Satterfield S; Wallace RB; Bauer DC; Palermo L; Wehren LE; Lombardi A; Santora AC; Cummings SR;
JAMA; 2006 Dec; 296(24):2927-38. PubMed ID: 17190893
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of monthly ibandronate in men with low bone density.
Orwoll ES; Binkley NC; Lewiecki EM; Gruntmanis U; Fries MA; Dasic G
Bone; 2010 Apr; 46(4):970-6. PubMed ID: 20060082
[TBL] [Abstract][Full Text] [Related]
19. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate.
Ettinger B; San Martin J; Crans G; Pavo I
J Bone Miner Res; 2004 May; 19(5):745-51. PubMed ID: 15068497
[TBL] [Abstract][Full Text] [Related]
20. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women.
Murphy MG; Weiss S; McClung M; Schnitzer T; Cerchio K; Connor J; Krupa D; Gertz BJ;
J Clin Endocrinol Metab; 2001 Mar; 86(3):1116-25. PubMed ID: 11238495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
